What are the recommended medication dosages for outpatient and hospitalized adult patients with community‑acquired pneumonia?

Medication Dosages for Community-Acquired Pneumonia

For outpatient adults with community-acquired pneumonia, use amoxicillin 1 g three times daily for healthy patients without comorbidities, or combination therapy with amoxicillin/clavulanate plus a macrolide (or respiratory fluoroquinolone monotherapy) for those with comorbidities; for hospitalized patients, use ceftriaxone 1-2 g once daily plus a macrolide or respiratory fluoroquinolone. 1

Outpatient Dosing Regimens

Healthy Adults Without Comorbidities

For otherwise healthy outpatient adults without risk factors for antibiotic-resistant pathogens, the following monotherapy options are recommended: 1

• Amoxicillin 1 g three times daily (strong recommendation, moderate quality evidence) 1
• Doxycycline 100 mg twice daily (conditional recommendation, low quality evidence) 1
• Macrolide monotherapy (only in areas with pneumococcal macrolide resistance <25%): 1
  • Azithromycin 500 mg on day 1, then 250 mg daily
  • Clarithromycin 500 mg twice daily
  • Clarithromycin extended-release 1,000 mg daily

Important caveat: Macrolide monotherapy should be avoided in areas with high pneumococcal resistance (≥25%), as this directly impacts clinical outcomes and mortality. 1

Outpatients With Comorbidities

For adults with chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia, use either combination therapy or fluoroquinolone monotherapy: 1

Combination Therapy Options:

• Beta-lactam component: 1
  • Amoxicillin/clavulanate 500 mg/125 mg three times daily, OR
  • Amoxicillin/clavulanate 875 mg/125 mg twice daily, OR
  • Amoxicillin/clavulanate 2,000 mg/125 mg twice daily, OR
  • Cefpodoxime 200 mg twice daily, OR
  • Cefuroxime 500 mg twice daily

PLUS one of the following:

• Azithromycin 500 mg on day 1, then 250 mg daily (strong recommendation for combination) 1
• Clarithromycin 500 mg twice daily or extended-release 1,000 mg daily (strong recommendation) 1
• Doxycycline 100 mg twice daily (conditional recommendation) 1

Monotherapy Alternative:

• Respiratory fluoroquinolone (strong recommendation, moderate quality evidence): 1
  • Levofloxacin 750 mg daily
  • Moxifloxacin 400 mg daily
  • Gemifloxacin 320 mg daily

Hospitalized Patient Dosing Regimens

Non-ICU Hospitalized Patients

For patients admitted to general medical wards with moderate severity pneumonia: 2, 3, 4

Preferred regimens:

• Ceftriaxone 1-2 g once daily IV plus a macrolide 2, 5, 3
• Cefotaxime 1 g three times daily IV plus a macrolide 2, 3
• Cefuroxime 750 mg every 8 hours IV plus erythromycin 6, 3
• Ampicillin/sulbactam IV plus a macrolide 3, 4

Macrolide component for hospitalized patients:

• Azithromycin 500 mg daily IV or oral 4
• Erythromycin 500 mg four times daily IV 2, 3
• Clarithromycin 500 mg twice daily 6

Alternative: Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily, moxifloxacin 400 mg daily) 3, 4

Key evidence note: A 2019 meta-analysis demonstrated that ceftriaxone 1 g daily is equally effective as 2 g daily for community-acquired pneumonia, with no difference in clinical cure rates (OR 1.02,95% CI 0.91-1.14). 5 This supports using the lower dose for non-severe cases to reduce costs and potential adverse effects.

ICU/Severe CAP Patients

For patients with severe community-acquired pneumonia requiring ICU admission: 2, 3, 4

Standard severe CAP regimen:

• Ceftriaxone 2 g once daily IV OR cefotaxime 1 g three times daily IV 2, 3

PLUS one of:

• Azithromycin 500 mg daily IV 4
• Levofloxacin 500-1,000 mg once daily IV 2, 3
• Moxifloxacin 400 mg once daily IV 2, 3

For Pseudomonas risk factors (bronchiectasis, severe COPD, recent hospitalization, recent broad-spectrum antibiotics): 4

• Antipseudomonal beta-lactam (piperacillin/tazobactam, cefepime, imipenem, meropenem, or doripenem)
• PLUS aminoglycoside
• PLUS azithromycin or antipseudomonal fluoroquinolone (levofloxacin or ciprofloxacin)

For MRSA risk factors (recent influenza, IV drug use, known MRSA colonization): 4

• Add vancomycin or linezolid to the above regimen

Treatment Duration

• Outpatient therapy: 7 days for uncomplicated cases 1, 2
• Hospitalized non-ICU patients: 7-10 days 2, 6
• ICU/severe CAP: 10-14 days 2

Common pitfall: Ten-day courses remain the most frequently prescribed duration in real-world practice, despite evidence supporting shorter courses for uncomplicated cases. 7 This represents unnecessary antibiotic exposure and should be avoided when patients demonstrate clinical improvement.

Transition from IV to Oral Therapy

Hospitalized patients should be switched from intravenous to oral antibiotics when they demonstrate: 4

• Clinical improvement (typically within first 3 days)
• Hemodynamic stability
• Ability to tolerate oral medications
• Normal gastrointestinal absorption

This early transition reduces costs, complications from IV access, and hospital length of stay without compromising outcomes. 4

Critical Stewardship Considerations

Fluoroquinolone restriction: Reserve respiratory fluoroquinolones for patients who have failed first-line therapy, have documented highly drug-resistant pneumococci (penicillin MIC ≥4 mcg/mL), or have true beta-lactam allergies to prevent emergence of fluoroquinolone resistance. 3

Declining broad-spectrum use: Real-world data from 2008-2019 shows broad-spectrum antibiotic use decreased from 45% to 19% in otherwise healthy patients, though 35% still received broad-spectrum agents not recommended by guidelines. 7 This highlights ongoing need for antimicrobial stewardship.

Vancomycin is NOT routinely indicated for community-acquired pneumonia or drug-resistant pneumococcal pneumonia unless MRSA is specifically suspected. 3